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BACKGROUND
Adult-onset inflammatory syndromes often manifest with overlapping clinical 
features. Variants in ubiquitin-related genes, previously implicated in autoinflam-
matory disease, may define new disorders.
METHODS
We analyzed peripheral-blood exome sequence data independent of clinical pheno-
type and inheritance pattern to identify deleterious mutations in ubiquitin-related 
genes. Sanger sequencing, immunoblotting, immunohistochemical testing, flow 
cytometry, and transcriptome and cytokine profiling were performed. CRISPR-Cas9–
edited zebrafish were used as an in vivo model to assess gene function.
RESULTS
We identified 25 men with somatic mutations affecting methionine-41 (p.Met41) 
in UBA1, the major E1 enzyme that initiates ubiquitylation. (The gene UBA1 lies 
on the X chromosome.) In such patients, an often fatal, treatment-refractory in-
flammatory syndrome develops in late adulthood, with fevers, cytopenias, charac-
teristic vacuoles in myeloid and erythroid precursor cells, dysplastic bone marrow, 
neutrophilic cutaneous and pulmonary inflammation, chondritis, and vasculitis. 
Most of these 25 patients met clinical criteria for an inflammatory syndrome (re-
lapsing polychondritis, Sweet’s syndrome, polyarteritis nodosa, or giant-cell arteritis) 
or a hematologic condition (myelodysplastic syndrome or multiple myeloma) or 
both. Mutations were found in more than half the hematopoietic stem cells, includ-
ing peripheral-blood myeloid cells but not lymphocytes or fibroblasts. Mutations 
affecting p.Met41 resulted in loss of the canonical cytoplasmic isoform of UBA1 
and in expression of a novel, catalytically impaired isoform initiated at p.Met67. 
Mutant peripheral-blood cells showed decreased ubiquitylation and activated in-
nate immune pathways. Knockout of the cytoplasmic UBA1 isoform homologue in 
zebrafish caused systemic inflammation.
CONCLUSIONS
Using a genotype-driven approach, we identified a disorder that connects seemingly 
unrelated adult-onset inflammatory syndromes. We named this disorder the VEXAS 
(vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome. (Funded by the 
NIH Intramural Research Programs and the EU Horizon 2020 Research and Innova-
tion Program.)
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Identifying the causes of systemic in-f lammatory diseases, particularly in adult populations, remains a challenge that lim-
its our understanding of the pathophysiology, 
prognosis, and treatment. Genetic approaches 
have provided important insights into patho-
genic mechanisms in both mendelian autoim-
mune1 and autoinflammatory2,3 diseases and in 
genetically complex disorders.4 Somatic muta-
tions, acquired and then clonally selected, have 
long been implicated in benign and neoplastic 
hematologic diseases5 but remain a poorly un-
derstood contributor to autoinflammatory and 
rheumatologic diseases; these mutations have 
been identified largely with the use of targeted 
sequencing approaches.6
The widespread availability of genomic DNA 
sequencing has led to genotype-driven ap-
proaches to delineate human disease.7-9 The 
starting point of this approach typically in-
volves bringing together a group of persons 
who have undergone genomic sequencing and 
who do not necessarily have similar pheno-
types. The objective is to find damaging vari-
ants in a common gene that underlie a previ-
ously unrecognized grouping of patients with 
particular clinical characteristics. These stud-
ies take advantage of shared genetic common-
alities, rather than clinical similarities, to 
overcome the limitations of recognizing dis-
crete phenotypes. Rheumatologic diseases may 
be well suited to this approach because of their 
complex and highly variable clinical presenta-
tions.
In the current study, we used a genotype-
driven approach to identify a genetic cause of 
inflammatory disease. We thereby identified 
recurrent and inactivating acquired mutations 
in UBA1, a gene encoding the ubiquitin-activating 
enzyme 1, in men with a late-onset, treatment-
refractory inflammatory syndrome with associ-
ated hematologic abnormalities. UBA1 is neces-
sary for the initiation of ubiquitylation, a type 
of post-translational modification of proteins 
that is used to regulate diverse aspects of cel-
lular biology, including intracellular signaling 
and protein degradation through the protea-
some or the autophagy–lysosome system. We 
named this disorder the VEXAS (vacuoles, E1 




Three affected men, each with a somatic UBA1 
variant, were identified by analysis of exome 
data from genetic databases at the National In-
stitutes of Health (NIH) Clinical Center. Fifteen 
additional men in observational cohorts at the 
NIH Clinical Center were identified on the basis 
of clinical similarities to the previous three af-
fected men: their somatic UBA1 variants were 
confirmed by Sanger sequencing. Seven other 
participants were identified in study populations 
at University College London and Leeds Teach-
ing Hospitals NHS Trust in the United Kingdom. 
All participants were enrolled in research stud-
ies that had been approved by the respective in-
stitutional review boards and provided written 
informed consent. Clinical diagnoses were de-
fined according to standard criteria.10-16
Genetic and Functional Analysis
We sequenced the exomes of the first 3 partici-
pants and 3 additional participants and sequenced 
UBA1 in the other 19 participants and their un-
affected family members. We prioritized genes 
involved in the post-translational process of 
ubiquitylation because of its regulation of innate 
immune responses.17 We analyzed fractionated 
cell types in blood and fibroblast samples ob-
tained from the participants using digital drop-
let polymerase-chain-reaction assay, immunob-
lotting, immunohistochemical testing, electron 
microscopy, flow cytometry, and cytokine pro-
filing. To study the effect of presumed etiologic 
variants on UBA1 function, we edited the ge-
nome of zebrafish using the CRISPR (clustered 
regularly interspaced short palindromic repeats)–
Cas9 (CRISPR-associated protein 9) system. The 
Supplementary Appendix, available with the full 
text of this article at NEJM.org, includes a descrip-
tion of the methods used for these procedures.
Statistical Analysis
Continuous variables are presented as means with 
standard deviations or medians with interquar-
tile ranges and were compared with the use of 
parametric or nonparametric tests as appropriate. 
Categorical variables are expressed as absolute 
numbers and percentages and were compared 
with the use of the chi-square test. Statistical 
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methods for the transcriptomic analyses are 
described in the Supplementary Appendix. Post 
hoc Bonferroni correction was performed for 
experiments with multiple comparisons, and the 
results are presented as adjusted P values.
R esult s
Genotype-First Screening to Identify  
the VEXAS Syndrome
We screened the exomes and genomes of 1477 
persons referred because of undiagnosed recur-
rent fevers, systemic inflammation, or both and 
1083 persons affected by atypical, unclassified 
disorders who were identified through the Un-
diagnosed Diseases Program.18 The combined 
population of participants was roughly balanced 
with respect to sex and spanned a wide range of 
ages (Fig. 1A). We identified 3 men, all with 
novel (absent from public databases including 
the Genome Aggregation Database), predicted 
deleterious, and apparently heterozygous variants 
at the same codon, methionine-41 (p.Met41) of 
the X-linked gene UBA1, which is highly intolerant 
to haploinsufficiency (as indicated by a “proba-
bility of being loss-of-function intolerant” [pLI] 
score of 1.0, on a range of 0.0 to 1.0, with a 
higher score indicating a greater degree of intol-
erance for loss-of-function variants in healthy 
persons). The seemingly heterozygous variants 
seen in these 3 affected men raised questions of 
mosaicism or aneuploidy, because males usually 
have only one copy of X-chromosomal genes. 
Mindful of the potential role of somatic muta-
tions in adult-onset disease, we evaluated all the 
variants, including those with a lower-than-
expected allele frequency.
We confirmed all UBA1 variants of interest 
using Sanger sequencing (Fig. 1A and Fig. S1 in 
the Supplementary Appendix) and determined 
that the variants were absent from fibroblasts in 
the tested participants (Fig. S2). None of the 25 
affected men had affected family members, and 
all 8 available relatives tested negative for the 
mutation. The participants did not have aneu-
ploidy on karyotype analysis, nor were X-chro-
mosomal copy-number variations present, as 
determined by high-density single nucleotide poly-
morphism array analysis (Fig. S2C). We therefore 
predicted that these apparently heterozygous 
variants were somatic (also known as mosaic or 
postzygotic) mutations, with genetically heter-
ogenous cells carrying either hemizygous wild-
type or mutated UBA1.20
To corroborate these findings, we interro-
gated exome data primarily from whole-blood 
samples obtained from 141,600 persons (77,162 
unaffected adults and 64,438 persons who had 
been referred for diagnostic testing, mostly for 
neurodevelopmental diseases) who had undergone 
sequencing at a diagnostic company (GeneDx). 
None of the unaffected persons had a UBA1 
p.Met41 allele fraction exceeding 5%. As for the 
affected persons, only 5%, the majority of whom 
were children, had immune phenotypes. How-
ever, we identified 3 men with UBA1 p.Met41 
variants exceeding 71% variant allele frequency 
(Table S1), all with late-onset inflammatory dis-
ease. Thus, both screens identified UBA1 p.Met41 
somatic mutations exclusively in men with adult-
onset inflammatory disorders.
Genetic Features of the VEXAS Syndrome
To characterize mosaicism, we isolated and se-
quenced different hematopoietic cell populations. 
The participants with UBA1 mosaic mutations 
had predominantly wild-type lymphocytes (T and 
B cells) and predominantly mutant myeloid cells 
(neutrophils and monocytes) in peripheral blood 
(Fig. 1B and 1C). Despite UBA1 mutations being 
lineage-restricted in the blood, early marrow pro-
genitor cells showed mosaicism. Hematopoietic 
stem cells and multipotent progenitors, granulo-
cyte–monocyte progenitors, megakaryocyte–ery-
throid progenitors, and lymphoid progenitors iso-
lated from bone marrow had abundant mutant 
cells, but mutations were absent in mature lym-
phocytes. The participants had decreased periph-
eral lymphocyte counts, which suggests that the 
mutant cells either did not proliferate or were 
eliminated, an outcome that resulted in an in-
creased proportion of the wild-type genotype 
(Fig. S3).
Clinical Features of the VEXAS Syndrome
The first 3 participants were men in whom se-
vere inflammatory syndromes had developed in 
the fifth to seventh decade of life. Common 
clinical features included alveolitis, ear and nose 
chondritis, skin lesions, and thromboembolic 
disease (Fig. 2). Each participant had progressive 
hematologic abnormalities, including macro-
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cytic anemia, thrombocytopenia, and myeloid 
dyspoiesis, but none had an overt hematologic 
malignant condition. The only common genetic 
lesion among these 3 participants was a nonsyn-
onymous missense mutation at UBA1 p.Met41 
(Fig. S4). We identified 22 additional partici-
pants who had overlapping clinical phenotypes; 
7 of these participants were from an existing 
cohort of patients with relapsing polychondritis 
(ClinicalTrials.gov number, NCT02257866) (Ta-
ble 1; see also the Supplementary Appendix). 
Among 18 participants who had undergone ge-
netic screening on the basis of their clinical 
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tory syndrome and cytopenia, as well as chon-
dritis, vasculitis, neutrophilic dermatosis, or a 
combination of these), 14 (78%) were found to 
have UBA1 mutations.
The 25 participants with confirmed mutations 
in UBA1 underwent extensive clinical assessment 
(Tables S2 through S8). All were male with a 
median age at disease onset of 64 years. Each of 
these participants had one of three somatic vari-
ants in codon 41 in UBA1 (predicting amino acid 
substitutions p.Met41Val [NM_003334.3:c.121A→G; 
ClinVar accession number, SCV001438043], 
p.Met41Thr [NM_003334.3:c.122T→C; ClinVar ac-
cession number, SCV001438045], or p.Met41Leu 
[NM_003334.3:c.121A→C; ClinVar accession num-
ber, SCV001438044]). The majority of these par-
ticipants had recurrent fevers, pulmonary involve-
ment, dermatologic manifestations (including 
neutrophilic dermatoses and cutaneous vasculi-
tis), macrocytic anemia, hematopoietic dyspoie-
sis, and bone marrow vacuolization restricted to 
myeloid and erythroid precursor cells (Table 1, 
Fig. 2, Table S3, and Figs. S5 and S6). Electron 
microscopy revealed myeloid cells that were un-
dergoing cell death and had vacuoles consisting 
of lipid droplets and disordered cellular organ-
elles, including degenerating mitochondria.
Subgroups of participants met or partially met 
established diagnostic or classification criteria 
for a number of clinical conditions (Table 1 and 
Table S2). Transformation into a myelodysplastic 
syndrome with excess blasts or acute myeloid 
leukemia did not occur in any participant. All 25 
participants had highly elevated levels of acute-
phase reactants and had no response to multiple 
disease-modifying antirheumatologic drugs (Ta-
bles S4 and S5). Glucocorticoids, often adminis-
tered in high doses, were the only treatment that 
consistently ameliorated severe inflammatory 
symptoms. Of the 25 participants, 10 (40%) died 
from disease-related causes (respiratory failure or 
progressive anemia) or complications related to 
treatment.
Immunologic Features of the VEXAS Syndrome
Transcriptome analysis of the peripheral blood of 
participants revealed a shared gene expression 
signature consistent with the activation of mul-
tiple innate immune pathways (Fig. S7A and S7B 
and Table S9). Gene-expression profiling of iso-
lated monocytes and neutrophils that were stud-
ied during a clinically quiescent period during 
which the participants had been receiving mini-
mal treatment showed highly activated inflam-
matory signatures in multiple pathways including 
tumor necrosis factor, interleukin-6, and inter-
feron-γ, a finding that is consistent with cell-
intrinsic severe myeloid inflammation (Fig. S7C 
and Tables S10 through S12). Activation of path-
ways affecting the unfolded protein response and 
integrated stress response was identified only in 
myeloid cells (Fig. S8).21 Elevated levels of mul-
tiple cytokines in the serum were consistent 
with the findings from the transcriptome analy-
sis (Fig. 3). Peripheral B cells and monocytes 
showed atypical differentiation, with loss of 
immature B cells and nonclassical and interme-
diate monocyte populations (Fig. S9). Functional 
studies of neutrophils obtained from the partici-
pants with the VEXAS syndrome, as compared 
with those from age- and sex-matched healthy 
controls, showed preserved phagocytic capacity 
in mutant cells but enhanced spontaneous neu-
trophil extracellular trap formation, findings that 
Figure 1 (facing page). Identification of Lineage-Restricted 
UBA1 Somatic Variants in the VEXAS Syndrome.
Panel A shows a schematic representation of a genotype‑
first screening approach to identify novel disease‑caus‑
ing variants and Sanger‑sequencing chromatograms for 
mosaic variants in Patients 1 through 3 at UBA1 methi‑
onine‑41 (p.Met41); the black triangles indicate the bases 
with distinct nucleotides. The term gnomAD denotes 
Genome Aggregation Database,19 pLI probability of be‑
ing loss‑of‑function intolerant (scores on the pLI range 
from 0.0 to 1.0, with a higher score indicating a greater 
degree of intolerance for loss‑of‑function variants in 
healthy persons), and VEXAS vacuoles, E1 enzyme,  
X‑linked, autoinflammatory, somatic. Panel B shows a 
dendrogram of hematopoietic differentiation with over‑
lying Sanger sequencing of sorted bone marrow pro‑
genitors and peripheral‑blood lineages from a repre‑
sentative case (in Patient 1). UBA1 mosaic variants 
were enriched in progenitor cells and myeloid lineages 
and were absent in lymphocytes. GMPs denotes gran‑
ulocyte–monocyte progenitors, HSCs hematopoietic 
stem cells, LPs lymphoid progenitors, MEPs megakary‑
ocyte–erythroid progenitors, and MPPs multipotent 
progenitors. Panel C shows quantification of variant 
 allele fraction with the use of digital droplet polymerase‑
chain‑reaction assay in isolated cell lines including pe‑
ripheral blood, fibroblasts, HSCs and MPPs, LPs, GMPs, 
and MEPs sorted from bone marrow–biopsy samples 
and neutrophils, monocytes, and T cells and B cells 
sorted from peripheral‑blood samples.
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are consistent with dysregulated proinflamma-
tory neutrophil activation (Fig. S10).
 VEXAS Syndrome and Loss of Cytoplasmic 
UBA1 Function
UBA1 encodes the major E1-activating enzyme 
required for initiation of all cellular ubiquitin 
signaling.22-25 UBA1 is expressed as two isoforms 
differing in translation start site — nuclear 
UBA1a (initiated at p.Met1) and cytoplasmic 
UBA1b (initiated at p.Met41) (Fig. 4A). Unexpect-
edly, monocytes obtained from the participants 
with the VEXAS syndrome, as compared with 
those from the controls, and ectopically expressed 
UBA1 Met41Val, as compared with the wild-type 
enzyme, had similar nuclear and cytoplasmic 
localization, despite loss of the initiating methio-
nine for UBA1b (Fig. S11A through S11C).
We next analyzed the expression of UBA1 
Met41 variants in human embryonic kidney 
(HEK293T) cells by immunoblotting, which re-
vealed loss of UBA1b and an unanticipated 
faster-migrating band (Fig. 4B and Fig. S11B). 
We hypothesized that the protein generating the 
faster-migrating band might be an isoform gen-
erated by translation initiation from a down-
stream start codon (Fig. 4A). Indeed, introduc-
tion of a mutation targeting the Met67 codon 
resulted in the disappearance of the faster- 
migrating band, suggesting that the transcrip-
tion of the messenger RNA of this novel isoform 
of UBA1, denoted here as UBA1c, is initiated 
from the Met67 codon. UBA1c localized to the 
cytoplasm (Fig. S11A), a finding consistent with 
our observations regarding monocytes from the 
participants with the VEXAS syndrome. Purified 
recombinant UBA1c was catalytically impaired 
in thioester assays, as compared with purified 
recombinant UBA1a and UBA1b, a finding that 
was indicated by the predominance of the faster-
migrating uncharged form in the UBA1c lane in 
contrast to the excess of charged forms with 
other tested UBA1 proteins (Fig. 4C). We there-
fore concluded that Met41 variants result in the 
reduction of cytoplasmic UBA1 function by fa-
voring the production of a catalytically deficient 
UBA1c over that of a catalytically proficient 
UBA1b.
Figure 2. Clinical Manifestations of the VEXAS Syndrome.
Lung involvement included pulmonary infiltrates and pleural effusions (Panel A), vasculitis of medium‑sized bronchial 
arteries (Panel B), and neutrophilic alveolitis (Panel C). Characteristic vacuoles were present in myeloid precursor cells 
from bone marrow aspirates (Panel D). Cutaneous manifestations included neutrophilic dermatosis with small‑ to 
medium‑vessel vasculitis (Panel E) and tender plaques (Panel F). Cartilaginous involvement included auricular chon‑
dritis (Panel G) and nasal chondritis (Panel H), which were sometimes associated with periorbital inflammation. He‑
matoxylin and eosin staining was used in Panels B, C, and E, and Wright–Giemsa staining was used in Panel D.
A B C D
E F G H
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We then attempted to confirm this cytoplas-
mic isoform switch by investigating the conse-
quences of such a switch in the cells from the 
participants. Purified T cells from the partici-
pants, which were predominantly wild type, and 
from the unaffected controls had equivalent 
amounts of UBA1a and UBA1b proteins (Fig. 4D). 
In contrast, monocytes, which predominantly 
carried mutated UBA1 variants in the partici-
pants, had decreased levels of UBA1b and de-
tectable levels of UBA1c, which confirmed the 
results of the transfection studies (Fig. 4D). 
Mutant monocytes were defective in ubiquity-
lation, as shown by a loss of polyubiquitin spe-
cies and a concomitant increase in free ubiquitin 
(Fig. 4D). These cells also showed increased 
eIF2α phosphorylation and altered LC3 levels, 
which suggests that loss of ubiquitylation acti-
vates cellular stress responses that lead to up-
regulation of the unfolded-protein response (as 
indicated by increased eIF2α phosphorylation) 
and dysregulation of autophagy (as indicated by 
altered LC3 levels) (Fig. 4D).
To study the contribution of nuclear and cyto-
plasmic UBA1 isoforms to inflammatory disease 
in vivo, we established CRISPR-Cas9–edited zebra-
fish models (Table S13). Zebrafish uba1 and hu-
man UBA1 are highly homologous (Fig. S12). 
Because uba1 is essential for viability,26-28 we as-
sessed inflammation during early development. 
Homozygous loss of all isoforms of Uba1 (Δuba1 
[Δ indicates loss of protein]) or loss of Uba1b 
alone (Δuba1b) but not Uba1a (Δuba1a) in trans-
genic Tg(mpx:EGFP [mpx promoter controlling 
expression of enhanced green fluorescent pro-
tein]) zebrafish led to lower numbers of neutro-
phils than the numbers in sibling control het-
erozygous or wild-type fish (Fig. S13). All three 
zebrafish lines deficient in uba1 also showed 
growth abnormalities and early death between 
7 and 21 days after fertilization, a finding that 
may be due in part to the germline nature of 
these mutations as compared with the somatic 
variants found in the participants with the 
VEXAS syndrome. Finally, Δuba1 or Δuba1b, but 
not Δuba1a, led to up-regulation of the expres-
sion of inflammatory genes in zebrafish, similar 
to that seen in the participants (Fig. 4E). Taken 
together, these results support the concept that 
systemic inflammation results from disruption 
of cytoplasmic UBA1 and its zebrafish homo-
logue.
Discussion
The genotype-first, phenotype-neutral strategy 
to understand human disease has yielded a 
positive outcome — the identification of a cause 
Table 1. Demographic and Clinical Characteristics of Participants  
with the VEXAS Syndrome.*
Characteristic Participants (N = 25)
Demographic characteristics
Male sex — no. (%) 25 (100)
Median age at onset (range) — yr 64 (45–80)
Died before the current study — no. (%) 10 (40)
Genetic characteristics
Somatic UBA1 (NM_003334.3) variant (p.Met41)  
— no. (%)
25 (100)
p.Met41Thr (c.122T→C) 15 (60)
p.Met41Val (c.121A→G) 5 (20)
p.Met41Leu (c.121A→C) 5 (20)
Key clinical features
Fever — no. (%) 23 (92)
Skin involvement — no. (%)† 22 (88)
Pulmonary infiltrate — no. (%) 18 (72)
Ear and nose chondritis — no. (%) 16 (64)
Venous thromboembolism — no. (%) 11 (44)
Macrocytic anemia — no. (%) 24 (96)
Bone marrow vacuoles — no./total no. (%) 18/18 (100)
Laboratory findings
Median C‑reactive protein (IQR) — mg/liter 73 (18–128)
Median ESR (IQR) — mm/hr 97 (64–124)
Current or past treatment
Glucocorticoids — no. (%) 25 (100)
Median no. of synthetic DMARDs (IQR)  2 (1–3)
Median no. of biologic or target synthetic DMARDs (IQR)   2 (0.5–3)
Diagnostic or classification criteria that were met — no. (%)
Relapsing polychondritis 15 (60)
Sweet’s syndrome 8 (32)
Myelodysplastic syndrome 6 (24)
Multiple myeloma or monoclonal gammopathy of  
undetermined significance
5 (20)
Polyarteritis nodosa 3 (12)
Giant‑cell arteritis 1 (4)
*  DMARDs denotes disease‑modifying antirheumatic drugs, ESR erythrocyte 
sedimentation rate, IQR interquartile range, and p.Met41 methionine‑41.
†  The most common skin‑biopsy findings were neutrophilic dermatosis (in 
8 participants), leukocytoclastic vasculitis (in 7 participants), and medium‑
vessel arteritis (in 3 participants).
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of severe adult-onset inflammatory disease. We 
identified myeloid lineage-restricted UBA1 somatic 
mutations as the common cause of clinically 
complex and seemingly disparate diagnoses with 
overlapping hematologic features.
Ubiquitylation is a three-step process per-
formed by the concerted actions of ubiquitin-
activating enzymes (E1), which include 2 unique 
enzymes29; ubiquitin-conjugating enzymes (E2), 
which include approximately 40 unique en-
zymes30; and substrate specific ligases (E3), 
which include more than 600 unique enzymes.31
Physiologic regulation of ubiquitin signaling 
often occurs at the level of E2 and E3 enzymes, 
but much less is known about control of ubiqui-
tin activation. Our finding that a major cause of 
the VEXAS syndrome is a depletion of cytoplasmic 
UBA1 supports a critical function of subcellu-
larly regulated ubiquitin activation during hema-
topoiesis.
UBA1 is required for nearly all cellular ubiqui-
tin signaling and is essential in model organ-
Figure 3. Serum Cytokines in Men with the VEXAS Syndrome.
Cytokine profiling was performed with the use of serum samples obtained 
from patients with the VEXAS syndrome, and the results were compared 
with those from controls. Enzyme‑linked immunosorbent assay revealed 
higher inflammatory markers in the patients with the VEXAS syndrome 
than in the controls. Panel A shows the results for C‑reactive protein values 
in the 25 participants with the VEXAS syndrome (values for the controls 
are not shown). The dashed line indicates the upper limit of the normal 
range (<5 mg per deciliter). Panel B shows the results for interleukin‑8, 
with median values of 14.4 mg per liter (interquartile range, 9.2 to 18.5) 
among 18 samples from 13 participants with the VEXAS syndrome and 
6.5 mg per liter (interquartile range, 5.1 to 8.6) among 12 controls. Panel C 
shows the results for interferon‑inducible protein 10 (IP‑10), with median 
values of 1995 pg per milliliter (interquartile range, 1443 to 3201) among 
18 samples from 13 participants with the VEXAS syndrome and 734 pg per 
milliliter (interquartile range, 564 to 893) among 12 controls. Panel D shows 
the results for interferon‑γ, with median values of 19.2 pg per milliliter (inter‑
quartile range, 11.4 to 23.3) among 14 samples from 13 participants with the 
VEXAS syndrome and 10.6 pg per milliliter (7.7 to 13.4) among 12 controls. 
In Panels B, C, and D, the long horizontal line represents the median value, 



















































































B Figure 4 (facing page). Loss of Cytoplasmic UBA1
Function Leading to Inflammation.
Panel A shows a schematic diagram with protein iso‑
forms and domains for UBA1. UBA1a is a long isoform 
with a nuclear localization sequence (NLS) and a trans‑
lation start site at p.Met1, and UBA1b is a short isoform 
without an NLS with a translation start site at p.Met41. 
AAD denotes active adenylation domain, FCCH first 
catalytic cysteine half‑domain, IAD inactive adenylation 
domain, SCCH second catalytic cysteine half‑domain, 
Ub ubiquitin, and UFD Ub fold domain. Panel B shows 
immunoblots of transfected human embryonic kidney 
(HEK293T) cells. Hemagglutinin (HA)‑tagged UBA1 
Met41 constructs lead to expression of a novel short 
isoform, abrogated by the introduction of a Met67Ala 
mutation. The term αHA denotes anti‑HA, and WT wild 
type. Panel C shows a representative Ub thioester for‑
mation assay with the use of purified recombinant UBA1 
isoforms. UBA1c shows impaired activity, whereas 
UBA1a p.Met41Val activity is similar to that in a UBA1a 
WT control. Ub thioester–charged forms of UBA1 vari‑
ants are labeled with “~Ub.” The quantification of five 
replicates is shown below in a bar chart. Thioester for‑
mation activity differed significantly between UBA1c 
and UBA1a WT (adjusted P<0.05). Panel D shows im‑
munoblots of isolated T cells and monocytes from three 
participants with the VEXAS syndrome and age‑matched 
controls. In the participants with the VEXAS syndrome, 
T cells are primarily WT and monocytes are primarily 
mutant. Mutant cells show decreased UBA1b and poly‑
ubiquitylation (Poly‑Ub) levels, an increased free Ub 
level, and increased eIF2α phosphorylation (p‑EIF2α) 
and LC3 levels. Glyceraldehyde‑3‑phosphate dehydroge‑
nase (GAPDH) was used as a loading control. Panel E 
shows higher levels of inflammatory gene expression in 
Δuba1 and Δuba1b embryos than in Δuba1a and sibling 
control heterozygous or WT control embryos (calculated 
as log10 factor change in the messenger RNA [mRNA] 
level). A Δ indicates loss of protein, and T bars standard 
errors. EF1‑α denotes elongation factor 1α, ISG15 inter‑
feron‑stimulated gene 15, and TNF tumor necrosis factor.
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isms and cultured cells. The identification of 
UBA1 variants exclusively in the somatic state 
probably reflects the finding that mutations af-
fecting p.Met41 are lethal when they are germ-
line and that this mutation is compatible with 
life only when mosaic in specific cell types.32,33
We observed that inflammation in the partici-
pants with the VEXAS syndrome is driven by 
mutant myeloid cells, which outnumber wild-
type myeloid cells. These findings suggest that 
myeloid precursor cells can survive with this 
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are negatively selected within bone marrow, ob-
servations that are consistent with the selective 
toxicity of the unfolded protein response and 
proteotoxic stress in lymphocytes as compared 
with myeloid cells.34 The fact that we identified 
this mutation only in men, all of whom were 
clinically affected, suggests that the additional 
allele in women protects against effects of the 
mutant allele, although it is possible that, owing 
to skewed X-inactivation, the disease is milder in 
women. More generally, our findings suggest 
that X-linked mosaic mutations may cause other 
diseases.
Somatic mutations in hematopoietic stem cells 
have long been known to be associated with 
myeloid cancers and bone marrow failure syn-
dromes and benign hematologic conditions such 
as paroxysmal nocturnal hemoglobinuria and, 
more recently, have been recognized as common, 
age-related processes, referred to as clonal hema-
topoiesis of indeterminate potential.35,36 Somatic 
mutations are also causally linked to T-cell– 
mediated dysregulation in pure red-cell aplasia37,38 
and large granular lymphocytosis.39 Myeloid-
restricted somatic mutations in UBA1 may under-
lie myelodysplastic disease, accompanied by sys-
temic inflammation. For example, hematologic 
abnormalities in the spectrum of myelodysplas-
tic syndrome develop in older men with relapsing 
polychondritis, with an increased risk of death.40 
The co-occurrence of relapsing polychondritis 
with myelodysplasia may be explained by the 
VEXAS syndrome. Similarly, concomitant myelo-
dysplasia has been reported in each of the rheu-
matologic conditions that were linked to the 
VEXAS syndrome in the current study, including 
polyarteritis nodosa, Sweet’s syndrome, and giant-
cell arteritis.41 Given the increased mortality 
among patients with the VEXAS syndrome, ef-
forts to identify effective treatment strategies 
that target the clonal somatic process, such as 
bone marrow transplantation or gene-editing 
therapies, should be considered.
Using a genotype-driven approach, we identi-
fied a disorder that connects seemingly unrelated 
adult-onset inflammatory syndromes. We named 
this genetic disorder the VEXAS syndrome, which 
is caused by myeloid-restricted somatic missense 
mutations in UBA1. Our findings show that so-
matic mutations can cause severe inflammatory 
conditions that manifest in adulthood.
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